Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.46 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.46 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 6/20 | 0.44 |
| ▸ | HTR3B | O95264 | 6/20 | 0.44 |
| ▸ | HTR3A | P46098 | 6/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 6/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 6/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177572 | 0.90 | SLC6A2 (0.52) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 | |
| SCHEMBL1177568 | 0.90 | SLC6A2 (0.52) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 | |
| Fumaric Acid SCHEMBL1178177 | 0.82 | HTR3E (0.50) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 | |
| Fumaric Acid SCHEMBL1177511 | 0.81 | HTR3E (0.49) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 | |
| Fumaric Acid SCHEMBL1177575 | 0.79 | HMOX1 (0.45) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 | |
| Fumaric Acid SCHEMBL1177484 | 0.77 | SLC6A2 (0.47) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 | |
| SCHEMBL1178259 | 0.76 | HCRTR2 (0.36) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Fumaric Acid SCHEMBL1177745 | 0.76 | SLC6A2 (0.46) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 | |
| Fumaric Acid SCHEMBL1178140 | 0.76 | SLC6A2 (0.46) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 | |
| Fumaric Acid SCHEMBL1178438 | 0.74 | OPRK1 (0.48) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112139-A1 | NOVEL 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | PETERS DAN | 2011-05-12 | — | — | US | disclosed |
| US-7888358-B2 | Serotonine, dopamine and norendrenaline receptors; antidepressants, anxiolytic agents, eating disorders; obesity; bipolar; drug abuse; neurodegenerative diseases | NEUROSEARCH A/S (DK) | 2011-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112139-A1 | NOVEL 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC18A3, SLC6A2 | SLC6A2 3/4885CHRM2 199/4885CHRM3 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.